Unicycive Therapeutics
UNCY
51 hedge funds and large institutions have $65.2M invested in Unicycive Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
46% more funds holding
Funds holding: 35 → 51 (+16)
37% more capital invested
Capital invested by funds: $47.5M → $65.2M (+$17.7M)
7.78% more ownership
Funds ownership: 38.32% → 46.09% (+7.8%)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
68% less call options, than puts
Call options by funds: $1.13M | Put options by funds: $3.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.52M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$1.47M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.14M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$1.02M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$937K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
-$819K |
| 2 |
PCM
Pavaki Capital Management
Pueblo,
Colorado
|
-$519K |
| 3 |
Squarepoint
New York
|
-$319K |
| 4 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$303K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$141K |
UNCY Hedge Fund Activity: Q1 2026 in Review
51 of the 8,203 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q1 2026, worth a combined $65.2M — up 37% from $47.5M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new UNCY positions and 3 closed out — a net gain of 17 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.52M. The largest seller was Cantor Fitzgerald, cutting an estimated $819K.
- 51 institutional investors held Unicycive Therapeutics (UNCY) as of Q1 2026, up from 35 in Q4 2025.
- Funds reported $65.2M of Unicycive Therapeutics stock for Q1 2026, up 37% quarter-over-quarter.
- 20 funds opened new Unicycive Therapeutics positions in Q1 2026 and 3 closed out, a net change of +17 holders.
- The largest Unicycive Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $2.52M added.
- The largest Unicycive Therapeutics seller in Q1 2026 was Cantor Fitzgerald, an estimated $819K sold.
Based on aggregated 13F filings for Q1 2026.